Terms: = Breast cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Clinical Outcome
24 results:
1. NAT10-mediated mRNA N4-acetylcytidine modification of MDR1 and bcrp promotes breast cancer progression.
Zhao CC; Sun X; Chen J; Geng BD
Thorac Cancer; 2024 Apr; 15(10):820-829. PubMed ID: 38409918
[TBL] [Abstract] [Full Text] [Related]
2. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract] [Full Text] [Related]
3. breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes.
Wang L; Simons DL; Lu X; Tu TY; Avalos C; Chang AY; Dirbas FM; Yim JH; Waisman J; Lee PP
EBioMedicine; 2020 Feb; 52():102631. PubMed ID: 31981982
[TBL] [Abstract] [Full Text] [Related]
4. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
Qin T; Huang G; Chi L; Sui S; Song C; Li N; Sun S; Li N; Zhang M; Zhao Z; Li L; Li M
Biomed Pharmacother; 2017 Nov; 95():649-655. PubMed ID: 28881292
[TBL] [Abstract] [Full Text] [Related]
5. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (abcg2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract] [Full Text] [Related]
6. abcg2/bcrp: Specific and Nonspecific Modulators.
Peña-Solórzano D; Stark SA; König B; Sierra CA; Ochoa-Puentes C
Med Res Rev; 2017 Sep; 37(5):987-1050. PubMed ID: 28005280
[TBL] [Abstract] [Full Text] [Related]
7. CES2, abcg2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
[TBL] [Abstract] [Full Text] [Related]
8. Polymorphisms of the drug transporters ABCB1, abcg2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Bruhn O; Cascorbi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
[TBL] [Abstract] [Full Text] [Related]
9. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
Chen DR; Lu DY; Lin HY; Yeh WL
Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
[TBL] [Abstract] [Full Text] [Related]
10. New prognostic factors in breast cancer.
Adam Maciejczyk A
Adv Clin Exp Med; 2013; 22(1):5-15. PubMed ID: 23468257
[TBL] [Abstract] [Full Text] [Related]
11. Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery.
Usuda J; Ichinose S; Ishizumi T; Ohtani K; Inoue T; Saji H; Kakihana M; Kajiwara N; Uchida O; Nomura M; Ohira T; Ikeda N
Lung Cancer; 2011 Nov; 74(2):332-7. PubMed ID: 21529984
[TBL] [Abstract] [Full Text] [Related]
12. Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology.
Hutson JR; Koren G; Matthews SG
Placenta; 2010 May; 31(5):351-7. PubMed ID: 20347140
[TBL] [Abstract] [Full Text] [Related]
13. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Hosono N; Tsunoda T; Kubo M; Tanigawara Y; Flockhart DA; Desta Z; Skaar TC; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
J Clin Oncol; 2010 Mar; 28(8):1287-93. PubMed ID: 20124171
[TBL] [Abstract] [Full Text] [Related]
14. Impact of breast cancer resistance protein on cancer treatment outcomes.
Ross DD; Nakanishi T
Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
[TBL] [Abstract] [Full Text] [Related]
15. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
Cascorbi I; Haenisch S
Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
[TBL] [Abstract] [Full Text] [Related]
16. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Kim YH; Ishii G; Goto K; Ota S; Kubota K; Murata Y; Mishima M; Saijo N; Nishiwaki Y; Ochiai A
Lung Cancer; 2009 Jul; 65(1):105-11. PubMed ID: 19036469
[TBL] [Abstract] [Full Text] [Related]
17. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer.
Vannini I; Zoli W; Tesei A; Rosetti M; Sansone P; Storci G; Passardi A; Massa I; Ricci M; Gusolfino D; Fabbri F; Ulivi P; Brigliadori G; Amadori D; Bonafe M
Tumour Biol; 2008; 29(3):145-51. PubMed ID: 18612219
[TBL] [Abstract] [Full Text] [Related]
18. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (bcrp) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
[TBL] [Abstract] [Full Text] [Related]
19. bcrp gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
Hu LL; Wang XX; Chen X; Chang J; Li C; Zhang Y; Yang J; Jiang W; Zhuang SM
Carcinogenesis; 2007 Aug; 28(8):1740-4. PubMed ID: 17494054
[TBL] [Abstract] [Full Text] [Related]
20. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.
Cascorbi I
Pharmacol Ther; 2006 Nov; 112(2):457-73. PubMed ID: 16766035
[TBL] [Abstract] [Full Text] [Related]
[Next]
